DCGI approves AstraZeneca’s Lynparza for adjuvant treatment of patients with high-risk early breast… EP News Bureau Aug 22, 2022 New data from Olympia phase-III trial suggest that Olaparib demonstrated a statistically significant and clinically meaningful…
